Quantcast
Home > Quotes > PBYI
PBYI

Puma Biotechnology Inc Common Stock (PBYI) Quote & Summary Data

$22.06
*  
0.06
0.27%
Get PBYI Alerts
*Delayed - data as of Nov. 13, 2018  -  Find a broker to begin trading PBYI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PBYI Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
69
Today's High / Low
$ 22.64 / $ 21.78
Share Volume
725,297
50 Day Avg. Daily Volume
1,405,712
Previous Close
$ 22.12
52 Week High / Low
$ 108.50 / $ 17.60
Market Cap
841,257,968
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.90
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.91

Intraday Chart

Shares Traded

Share Volume:
725,297
50 Day Avg. Daily Volume:
1,405,712

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.90

Trading Range

The current last sale of $22.06 is 25.34% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 22.64 $ 108.50
 Low: $ 21.78 $ 17.60

Company Description (as filed with the SEC)

Unless otherwise provided in this Annual Report, references to the "Company," "we," "us," and "our" refer to Puma Biotechnology, Inc., a Delaware corporation formed on April 27, 2007 and formerly known as Innovative Acquisitions Corp., together with its wholly-owned subsidiary, Puma Biotechnology Ltd., and all references to "Former Puma" refer to Puma Biotechnology, Inc., a privately-held Delaware corporation formed on September 15, 2010, that merged with and into us in October 2011. We refer to this transaction as the "Merger." We are a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. We in-license the global development and commercialization rights to three drug candidates - PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.  ... More ...  


Risk Grade

Where does PBYI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 22.47
Open Date:
Nov. 13, 2018
Close Price:
$ 22.06
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x